BAYN Stock Analysis: Bayer NA | XETRA
Drug Manufacturers - General | XETRA, Germany | Market Cap: 43.001m EUR | 12M Return: 58.4% | DE000BAY0017 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 107M
EPS Trend: -78.7%
Qual. Beats: 2
Rev. Trend: -98.5%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Bayer AG is a German life science company operating across three main segments: Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division focuses on prescription products in cardiology, womens health, oncology, hematology, ophthalmology, and diagnostic imaging, while the Consumer Health segment provides over-the-counter medicines, nutritional supplements, and self-care products. The Crop Science segment offers crop protection, seeds, plant traits, and digital agriculture solutions to farmers globally.
Distribution channels span wholesalers, pharmacies, supermarkets, online retailers, hospitals, and direct-to-farmer sales, reflecting the companys diversified business model. Bayer is headquartered in Leverkusen, Germany, and was founded in 1863, making it one of the longest-operating players in the global pharmaceutical and agrochemical industries.
The company maintains several strategic partnerships, including alliances with The University of Colorado Anschutz, UCHealth, Childrens Hospital Colorado, and Henry Ford Health to advance drug development and clinical trials, as well as a commercial agreement with Neste to scale new winter canola for biofuel production. Bayers combination of pharmaceutical, consumer health, and agricultural science operations places it among the few large-cap companies that straddle both the healthcare and agribusiness sectors.
- Roundup litigation costs and verdicts weigh on earnings
- Xarelto and Eylea face patent cliff from biosimilars
- Crop Science margins hinge on glyphosate pricing and volumes
| Net Income: -1.74b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -3.01 > 1.0 |
| NWC/Revenue: 3.03% < 20% (prev 8.60%; Δ -5.57% < -1%) |
| CFO/TA 0.04 > 3% & CFO 4.16b > Net Income -1.74b |
| Net Debt (34.6b) to EBITDA (5.08b): 6.82 < 3 |
| Current Ratio: 1.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (982.4m) vs 12m ago 0.0% < -2% |
| Gross Margin: 59.05% > 18% (prev 54.95%; Δ 4.10% > 0.5%) |
| Asset Turnover: 42.70% > 50% (prev 43.88%; Δ -1.17% > 0%) |
| Interest Coverage Ratio: 0.52 > 6 (EBIT TTM 1.33b / Interest Expense TTM 2.55b) |
| A: 0.01 (Total Current Assets 33.6b - Total Current Liabilities 32.3b) / Total Assets 107b |
| B: 0.06 (Retained Earnings 6.73b / Total Assets 107b) |
| C: 0.01 (EBIT TTM 1.33b / Avg Total Assets 106b) |
| D: 0.38 (Book Value of Equity 29.6b / Total Liabilities 77.6b) |
| Altman-Z'' = 0.77 = B |
| DSRI: 1.04 (Receivables 14.9b/14.6b, Revenue 45.4b/46.2b) |
| GMI: 0.93 (GM 54.95% / 59.05%) |
| AQI: 1.01 (AQ_t 0.57 / AQ_t-1 0.56) |
| SGI: 0.98 (Revenue 45.4b / 46.2b) |
| TATA: -0.05 (NI -1.74b - CFO 4.16b) / TA 107b) |
| Beneish M = -3.07 (Cap -4..+1) = AA |
As of October 13, 2026, the stock is trading at EUR 43.83 with a total of 1,220,972 shares traded. Over the past week, the price has changed by -0.30%, over one month by -11.15%, over three months by -12.20% and over the past year by +58.37%.
Current recommended Stop Loss: 42.20 (which is 3.7% or 1.2 ATR below the current price).
Bayer NA has no consensus analysts rating.
P/E Forward = 10.6383
P/S = 0.9477
P/B = 1.6455
P/EG = 4.7193
Revenue TTM = 45.4b EUR
EBIT TTM = 1.33b EUR
EBITDA TTM = 5.08b EUR
Long Term Debt = 30.8b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 7.27b EUR (from shortTermDebt, last quarter)
Debt = 39.7b EUR (from shortLongTermDebtTotal, last quarter) + Leases 1.29b
Net Debt = 34.6b EUR (calculated: Debt 39.7b - CCE 5.08b)
Enterprise Value = 77.6b EUR (43.0b + Debt 39.7b - CCE 5.08b)
Interest Coverage Ratio = 0.52 (Ebit TTM 1.33b / Interest Expense TTM 2.55b)
EV/FCF = 53.54x (Enterprise Value 77.6b / FCF TTM 1.45b)
FCF Yield = 1.87% (FCF TTM 1.45b / Enterprise Value 77.6b)
FCF Margin = 3.20% (FCF TTM 1.45b / Revenue TTM 45.4b)
Net Margin = -3.83% (Net Income TTM -1.74b / Revenue TTM 45.4b)
Gross Margin = 59.05% ((Revenue TTM 45.4b - Cost of Revenue TTM 18.6b) / Revenue TTM)
Gross Margin QoQ = 58.24% (prev 60.97%)
Tobins Q-Ratio = 0.72 (Enterprise Value 77.6b / Total Assets 107b)
Interest Expense / Debt = 6.42% (Interest Expense 2.55b / Debt 39.7b)
Taxrate = 28.66% (92.0m / 321.0m)
NOPAT = 946.7m (EBIT 1.33b * (1 - 28.66%))
Current Ratio = 1.04 (Total Current Assets 33.6b / Total Current Liabilities 32.3b)
Debt / Equity = 1.34 (Debt 39.7b / totalStockholderEquity, last quarter 29.6b)
Debt / EBITDA = 6.82 (Net Debt 34.6b / EBITDA 5.08b)
Debt / FCF = 23.89 (Net Debt 34.6b / FCF TTM 1.45b)
Total Stockholder Equity = 28.5b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.64% (Net Income -1.74b / Total Assets 107b)
RoE = -6.10% (Net Income TTM -1.74b / Total Stockholder Equity 28.5b)
RoCE = 2.24% (EBIT 1.33b / Capital Employed (Equity 28.5b + L.T.Debt 30.8b))
RoIC = 1.18% (NOPAT 946.7m / Invested Capital 80.0b)
WACC = 6.19% (E(43.0b)/V(82.7b) * Re(7.68%) + D(39.7b)/V(82.7b) * Rd(6.42%) * (1-Tc(0.29)))
Discount Rate = 7.68% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 8.70 | Cagr: 0.0%
[DCF] Terminal Value 73.10% ; FCFF base≈2.71b ; Y1≈2.37b ; Y5≈1.92b
[DCF] Fair Price = N/A (negative equity: EV 30.8b - Net Debt 34.6b = -3.84b; debt exceeds intrinsic value)
EPS Correlation: -78.70 | EPS CAGR: -8.76% | SUE: 0.90 | # QB: 2
Revenue Correlation: -98.54 | Revenue CAGR: -1.97% | SUE: 1.00 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.40 | Chg30d=-8.99% | Revisions=-62% | Analysts=6
EPS current Year (2026-12-31): EPS=4.54 | Chg30d=-0.06% | Revisions=+10% | GrowthEPS=-7.5% | GrowthRev=+0.7%
EPS next Year (2027-12-31): EPS=4.84 | Chg30d=+0.10% | Revisions=-10% | GrowthEPS=+6.5% | GrowthRev=+2.5%
[Analyst] Revisions Ratio: -23% (up=7, down=12)